Search 

TIF is a VC investor specializing in early stage biotech companies in China.

Viva BioInnovator ("VBI") is the investment division of Viva Biotech Holdings (1873.HK). We are solely dedicated to the identification and success of early-stage, biotech start-ups for Viva’s incubation, equity-for-service, and investment platforms. Our commitment is to operate a collaborative platform for innovative biotech companies from around the world, and for anyone aiming to develop an idea with transformative or strong potential.

Gene Therapy company delivering Intrabodies with AAV delivery targeting misfolded proteins in neurodegenerative diseases. INT41 for Huntington’s Disease is our flagship product with successful results in cell based and animal models for Huntington's disease with additional indications. INT41 has Orphan Designation from the FDA.

Our platform selects Intrabodies that target novel intracellular mutations or stabilize refolding and can be applied to multiple therapeutic areas. 

Zhejiang Jianfeng Pharmaceutical Co., Ltd., founded on Dec. 30th, 1998, is a wholly-owned subsidiary of listed company Zhejiang Jianfeng Group Co., Ltd. (SHA: 600668). 　　Our company consists of five industrial enterprises, three commercial enterprises, three scientific institutions and two mobile postdoctoral stations. It is one of National Top 100 Pharmaceutical Enterprises, one of Top 10 Pharmaceutical Industrial Enterprises of Zhejiang Province, National Key High-tech Enterprise, National high-tech Industrialization Demonstration Project Enterprise, Innovative Demonstration Enterprise of Zhejiang Province, and AAA-level Contract-honoring and Promise-keeping Enterprise of Zhejiang Province.

Our key products include Aspartic Acid Amlodipine Tablets, Aceclofenac Sustained-release Tablets, Paroxetine Hydrochloride Tablets, Cefmenoxime Hydrochloride for Injection, Yufeng Ningxin Drop Pills, Penciclovir for Injection, Sodium Hyaluronate Eye Drops, and etc.

Adhering to the corporate spirit of “Aiming for Top One, Producing Fine Medicine”, pursuing business philosophy of “science and technology achieve health”, our company has been oriented by the development of bulk pharmaceutical chemicals with high technology content and high-added value, and new chemical medicine preparations and aided by the natural products extraction and proprietary Chinese medicine preparations. Meanwhile, our company is paying attention to the development method of new biological agent medicine, and will enter into the health product field in good time. We now have a main line with three major series products, which are anti-infection medicine, cardiovascular medicine, and anti-depression medicine. Depending on first-rate business philosophy, first-rate production management and first-rate products, our company will create a famous brand that is trusted by the public, and contribute to the health of human.

研发生产企业

唯好诊所研究院是一家美国社区精神卫生诊所和临床研究机构, 发展新型医疗卫生保健系统, 从事跨国境脑疾病医疗健康业务商业拓展和知识产权许可转让及并购整合.

康弘是一家致力于中药、化药和生物药研发、生产、销售及售后服务的大型医药集团。

专注于儿科品种

深圳未知君生物科技有限公司成立于2017年,是China首家专注于肠道微生物治疗的AI制药公司,拥有先进完备的微生物药物研发平台。公司旨在通过粪菌移植、配方菌等微生物治疗方式,改善或重建患者肠道菌群,实现肠道及系统性疾病的缓解或治疗。

generic pharmaceutical listed company